Advanced search
1 file | 214.77 KB Add to list

Local inflammation in chronic upper airway disease

LIEN CALUS (UGent) , Thibaut Van Zele (UGent) , Lara Derycke (UGent) , Olga Krysko (UGent) , TINEKE DUTRE (UGent) , Peter Tomassen (UGent) , Melissa Dullaers (UGent) , Claus Bachert (UGent) and Philippe Gevaert (UGent)
(2012) CURRENT PHARMACEUTICAL DESIGN. 18(16). p.2336-2346
Author
Organization
Abstract
Chronic Rhinosinusitis (CRS), a chronic upper airway inflammation, is an inflammation of the nose and the paranasal cavities and is highly prevalent. Chronic rhinosinusitis is currently classified as CRS with nasal polyps or CRS without nasal polyps. This review highlights the pathophysiological differences in CRS on remodeling and on T-cell patterns. Nasal polyps have a high co-morbidity with the lower airway inflammatory disease, asthma. Evidence is accumulating for the role of superantigens, Staphylococcus aureus enterotoxins, in CRS with nasal polyps and asthma, both T helper 2-biased diseases. Until today there are no biomarkers involved in the diagnosis of CRS or the treatment follow-up. Further differentiation of the phenotype of the disease is needed, which will reflect in the development of new biomarkers and in new innovative treatment options. Defining and predicting response to therapy in individual CRS patients is a challenge for future research.
Keywords
CHRONIC RHINOSINUSITIS, FC-EPSILON-RI, Chronic rhinosinusitis, asthma, treatment, inflammation, AUREUS ENTEROTOXIN-B, THYMIC STROMAL LYMPHOPOIETIN, FREE LIGHT-CHAINS, HOUSE-DUST MITE, NASAL POLYPS, OBSTRUCTIVE PULMONARY-DISEASE, ADAPTIVE IMMUNE-RESPONSES, ANTIGEN-PRESENTING CELLS

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 214.77 KB

Citation

Please use this url to cite or link to this publication:

MLA
CALUS, LIEN, et al. “Local Inflammation in Chronic Upper Airway Disease.” CURRENT PHARMACEUTICAL DESIGN, vol. 18, no. 16, 2012, pp. 2336–46.
APA
CALUS, L., Van Zele, T., Derycke, L., Krysko, O., DUTRE, T., Tomassen, P., … Gevaert, P. (2012). Local inflammation in chronic upper airway disease. CURRENT PHARMACEUTICAL DESIGN, 18(16), 2336–2346.
Chicago author-date
CALUS, LIEN, Thibaut Van Zele, Lara Derycke, Olga Krysko, TINEKE DUTRE, Peter Tomassen, Melissa Dullaers, Claus Bachert, and Philippe Gevaert. 2012. “Local Inflammation in Chronic Upper Airway Disease.” CURRENT PHARMACEUTICAL DESIGN 18 (16): 2336–46.
Chicago author-date (all authors)
CALUS, LIEN, Thibaut Van Zele, Lara Derycke, Olga Krysko, TINEKE DUTRE, Peter Tomassen, Melissa Dullaers, Claus Bachert, and Philippe Gevaert. 2012. “Local Inflammation in Chronic Upper Airway Disease.” CURRENT PHARMACEUTICAL DESIGN 18 (16): 2336–2346.
Vancouver
1.
CALUS L, Van Zele T, Derycke L, Krysko O, DUTRE T, Tomassen P, et al. Local inflammation in chronic upper airway disease. CURRENT PHARMACEUTICAL DESIGN. 2012;18(16):2336–46.
IEEE
[1]
L. CALUS et al., “Local inflammation in chronic upper airway disease,” CURRENT PHARMACEUTICAL DESIGN, vol. 18, no. 16, pp. 2336–2346, 2012.
@article{3000595,
  abstract     = {{Chronic Rhinosinusitis (CRS), a chronic upper airway inflammation, is an inflammation of the nose and the paranasal cavities and is highly prevalent. Chronic rhinosinusitis is currently classified as CRS with nasal polyps or CRS without nasal polyps. This review highlights the pathophysiological differences in CRS on remodeling and on T-cell patterns. Nasal polyps have a high co-morbidity with the lower airway inflammatory disease, asthma. Evidence is accumulating for the role of superantigens, Staphylococcus aureus enterotoxins, in CRS with nasal polyps and asthma, both T helper 2-biased diseases. Until today there are no biomarkers involved in the diagnosis of CRS or the treatment follow-up. Further differentiation of the phenotype of the disease is needed, which will reflect in the development of new biomarkers and in new innovative treatment options. Defining and predicting response to therapy in individual CRS patients is a challenge for future research.}},
  author       = {{CALUS, LIEN and Van Zele, Thibaut and Derycke, Lara and Krysko, Olga and DUTRE, TINEKE and Tomassen, Peter and Dullaers, Melissa and Bachert, Claus and Gevaert, Philippe}},
  issn         = {{1381-6128}},
  journal      = {{CURRENT PHARMACEUTICAL DESIGN}},
  keywords     = {{CHRONIC RHINOSINUSITIS,FC-EPSILON-RI,Chronic rhinosinusitis,asthma,treatment,inflammation,AUREUS ENTEROTOXIN-B,THYMIC STROMAL LYMPHOPOIETIN,FREE LIGHT-CHAINS,HOUSE-DUST MITE,NASAL POLYPS,OBSTRUCTIVE PULMONARY-DISEASE,ADAPTIVE IMMUNE-RESPONSES,ANTIGEN-PRESENTING CELLS}},
  language     = {{eng}},
  number       = {{16}},
  pages        = {{2336--2346}},
  title        = {{Local inflammation in chronic upper airway disease}},
  volume       = {{18}},
  year         = {{2012}},
}

Web of Science
Times cited: